Overview Request Sample Pages Request Customization Download PDF
You are viewing: GCC Countries Preimplantation Genetic Testing Market analysis

The GCC Countries Preimplantation Genetic Testing Market was valued at $0.76 Million in 2025 and projected to reach to $1.2 Million by 2030, representing a compound annual growth rate of 9.6%. The Preimplantation Genetic Testing market in GCC Countries is positioned for steady growth, driven by rising infertility prevalence and substantial healthcare sector investments.

GCC Countries Preimplantation Genetic Testing Market (2025-2030) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

GCC Countries Preimplantation Genetic Testing Market Trends and Insights

  • GCC Countries are witnessing increased adoption of advanced reproductive technologies, driven by rising infertility rates, growing healthcare infrastructure investment, and heightened awareness of genetic screening benefits among affluent populations.
  • The region's strong healthcare spending and regulatory support for assisted reproductive technologies position GCC Countries as a key growth market in the Middle East. GCC Countries' market growth is underpinned by improving access to fertility clinics, rising disposable incomes, and cultural shifts toward preventive genetic medicine.
  • The 9.6% compound annual growth rate reflects GCC Countries' commitment to modernizing reproductive healthcare services and attracting medical tourism.
  • By 2030, GCC Countries is expected to consolidate its position as a regional leader in PGT adoption, supported by continued investment in diagnostic capabilities and patient education initiatives..

Key Market Statistics

  • CAGR (2025-2030) 9.6% CAGR
  • Market Size, 2025 ~USD 0.76 Million
  • Forecast, 2030 ~USD 1.2 Million
  • Country GCC Countries

GCC Countries Preimplantation Genetic Testing Market Overview

Market Valuation Growth :

GCC Countries' Preimplantation Genetic Testing market is valued at $0.76 million in 2025, with projections reaching $1.20 million by 2030, representing a robust 9.6% CAGR over the forecast period.

Rising Infertility Awareness :

Increased infertility rates across GCC nations are driving demand for advanced reproductive technologies, with genetic screening becoming a preferred solution among affluent populations seeking optimal health outcomes.

Healthcare Infrastructure Investment :

GCC Countries are significantly investing in modern fertility clinics and diagnostic centers, enhancing accessibility to preimplantation genetic testing services and supporting market expansion.

Genetic Screening Adoption :

Growing awareness of genetic screening benefits among GCC populations is accelerating PGT adoption, supported by improved healthcare literacy and increasing acceptance of assisted reproductive technologies.

GCC Countries Preimplantation Genetic Testing Market Dynamics

  • The region's affluent demographics and advanced medical infrastructure create favorable conditions for premium reproductive technologies.
  • Increasing consumer awareness regarding genetic health screening and hereditary disease prevention is propelling market expansion. Looking ahead, GCC Countries will likely see enhanced adoption through improved clinic accessibility, competitive pricing strategies, and regional regulatory frameworks supporting genetic testing.
  • Strategic partnerships between international fertility centers and local healthcare providers will further accelerate market penetration, positioning the region as a growing hub for assisted reproductive technologies in the Middle East..

Related Ecosystem

Advanced Genetic Sequencing

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Reagents
  • Assay Kits
  • Bioinformatics
  • Flow Cytometry
Top Companies
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • Agilent Technologies, Inc.
  • Qiagen N.V.
  • Danaher Corporation

    Biotechnology

    Top Technologies
    • Reagents
    • Polymerase Chain Reaction (PCR)
    • Stem Cells
    • Assay Kits
    • Flow Cytometers
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Danaher Corporation
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.

      Key Takeaways

      • GCC Countries PGT market valued at $0.76M in 2025, growing to $1.20M by 2030 at 9.6% CAGR
      • Rising infertility rates and healthcare infrastructure investment are primary growth drivers in GCC Countries
      • GCC Countries benefits from high disposable incomes and strong regulatory support for reproductive technologies
      • Medical tourism and preventive genetic medicine adoption position GCC Countries as a regional market leader

      Preimplantation Genetic Testing Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment SINGLE GENE DISORDERS (Application)
      Forecast Period 2025–2030
      Growth Rate CAGR of 10.5% from 2025 to 2030
      Largest Segment PREIMPLANTATION GENETIC SCREENING (Procedure Type)
      Market Size Base Year (Billions) ~USD 0.69 (2025)
      Revenue Forecast (Billions) ~USD 1.14 (2030)
      Segments Covered Product & Service, Procedure Type, Technology, Application, Type, Type Of Cycle, End User

      GCC Countries Preimplantation Genetic Testing Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Procedure Type

      • Preimplantation Genetic Diagnosis
      • Preimplantation Genetic Screening

      By Technology

      • Comparative Genomic Hybridization
      • Fluorescence In Situ Hybridization
      • Next-Generation Sequencing
      • Polymerase Chain Reaction
      • Single-Nucleotide Polymorphism

      By Application

      • Aneuploidy
      • Gender Identification
      • Hla Typing
      • Single Gene Disorders
      • Structural Chromosomal Abnormalities
      • X-Linked Disorders

      By Type

      • Deletions
      • Duplications
      • Inversions
      • Translocations

      By Type Of Cycle

      • Fresh Donor
      • Fresh Non-Donor
      • Frozen Donor
      • Frozen Non-Donor

      By End User

      • Diagnostic Laboratories
      • Fertility Clinics
      • Hospitals
      • Other End Users

      Target Audience

      • Fertility Clinic Operators : Clinic owners and managers in GCC Countries need regional market data to assess growth opportunities, optimize service offerings, and plan facility expansions in response to rising PGT demand.
      • Diagnostic Laboratory Providers : Lab operators require GCC-specific insights to understand market size, competitive positioning, and technology adoption rates to guide investment in genetic testing infrastructure and capabilities.
      • Medical Device & Technology Companies : Manufacturers of PGT equipment and software solutions need regional market intelligence to identify sales opportunities, develop localized products, and establish distribution partnerships in GCC nations.
      • Healthcare Investors & PE Firms : Investment professionals evaluating reproductive healthcare opportunities in the Gulf region require detailed market forecasts and growth drivers specific to GCC Countries for portfolio decisions.
      • Healthcare Policy & Regulatory Bodies : Government agencies and health ministries in GCC Countries need market data to inform regulatory frameworks, healthcare planning, and resource allocation for genetic testing services.

      Key Companies in the GCC Countries Preimplantation Genetic Testing Market

      CompanyHQOwnershipStrongest segments
      CIMARON LABELPressure-sensitive paper labels,Film and durable labels,Specialty/custom applications,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLaboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments,
      AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
      REVVITYUnited StatesPublic CompanyReagents, Assays, and Consumables,Instruments and Detection/Imaging Platforms,Software, Subscriptions, and Informatics,
      COOPERCOMPANIESUnited StatesPublic CompanySpherical contact lenses,Toric and multifocal contact lenses,Fertility consumables, equipment, and services,
      ABBOTTUnited StatesPublic CompanyDiagnostic Products,Medical Devices,Nutritional Products,
      TAKARA BIO INC.JapanPrivate CompanyResearch reagents for genetic and cellular research,Instruments (PCR instruments and cellular analysis devices),In vitro diagnostics (including COVID-19 testing),
      VITROLIFESwedenPublic CompanyIVF media and oil,Labware (dishes, pipettes, tubes, VitroTemp, eWitness-related consumables),Cryopreservation solutions,

      CIMARON LABEL

      Insufficient information provided to generate description.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a United States-based public company founded in 1956 with 125,000 employees. The company is a global leader in serving science, providing laboratory equipment, reagents, and analytical instruments.

      AGILENT TECHNOLOGIES, INC.

      Agilent Technologies, Inc. is a United States-based public company founded in 1999 with 18,000 employees. The company provides life sciences, diagnostics, and applied chemical markets with instruments and software.

      REVVITY

      Revvity is a United States-based public company founded in 1937 with 11,000 employees. The company provides analytical technologies and solutions for research, diagnostics, and applied markets.

      COOPERCOMPANIES

      CooperCompanies is a United States-based public company founded in 1958 with 15,000 employees. The company operates in the medical device sector, primarily focused on contact lenses and eye care products.

      ABBOTT

      Abbott is a United States-based public company founded in 1888 with 115,000 employees. The company is a diversified healthcare manufacturer producing pharmaceuticals, diagnostics, nutritional products, and medical devices.

      TAKARA BIO INC.

      Takara Bio Inc. is a Japan-based private company founded in 2002 with 1,779 employees. The company specializes in biotechnology research and development.

      VITROLIFE

      Vitrolife is a Sweden-based public company founded in 1989 with 1,103 employees. The company develops and manufactures products for assisted reproduction and embryo culture.

      Reasons to Buy this Report

      • Regional Market Sizing : Obtain precise market valuation data specific to GCC Countries, including 2025 baseline ($0.76M) and 2030 forecasts ($1.20M), enabling accurate business planning and investment decisions.
      • Growth Trajectory Analysis : Understand the 9.6% CAGR specific to GCC Countries versus the 10.5% global rate, identifying regional growth dynamics and competitive positioning opportunities within the Gulf market.
      • Infertility & Adoption Drivers : Access insights into rising infertility rates, healthcare infrastructure investments, and genetic screening awareness unique to GCC populations, informing targeted market entry strategies.
      • Competitive Landscape Intelligence : Benchmark against regional market trends and identify gaps in GCC Countries' fertility clinic networks, diagnostic capabilities, and service offerings for strategic differentiation.
      • Investment & Expansion Planning : Leverage GCC-specific market data to evaluate expansion feasibility, partnership opportunities, and revenue projections for fertility centers, diagnostic labs, and reproductive technology providers.

      Frequently asked questions

      What is the current market size of PGT in GCC Countries?

      The Preimplantation Genetic Testing market in GCC Countries was valued at $0.76 million in 2025.

      What is the projected market size for GCC Countries by 2030?

      GCC Countries' PGT market is forecast to reach $1.20 million by 2030, representing significant regional growth.

      What is the CAGR for PGT in GCC Countries?

      The Preimplantation Genetic Testing market in GCC Countries is expected to grow at a compound annual growth rate of 9.6% from 2025 to 2030.

      What factors are driving PGT market growth in GCC Countries?

      Key drivers in GCC Countries include rising infertility rates, increased healthcare infrastructure investment, growing awareness of genetic screening, high disposable incomes, and strong regulatory support for assisted reproductive technologies.

      How does GCC Countries compare to the global PGT market?

      GCC Countries' 9.6% CAGR is slightly below the global average of 10.5%, though the region maintains a higher estimated market size relative to its population, reflecting strong adoption rates.

      RESEARCH METHODOLOGY

      This research extensively used secondary sources, directories, and databases to gather valuable information for analyzing the global preimplantation genetic testing market. In-depth interviews were conducted with various primary respondents, including key industry players, subject-matter experts (SMEs), C-level executives, and industry consultants, to obtain and verify important qualitative and quantitative data and evaluate the market’s growth prospects. The global market size estimated through secondary research was cross-checked with inputs from primary research to determine the final market size.

      Secondary Research

      Secondary research was mainly used to gather information for the detailed technical, market, and commercial analysis of the preimplantation genetic testing market. The secondary sources for this study include the World Health Organization (WHO), World Bank, Human Fertilization and Embryology Authority (HFEA), International Federation of Fertility Societies (IFFS), American Society for Reproductive Medicine (ASRM), Australia and New Zealand Assisted Reproduction Database (ANZARD), Centers for Disease Control and Prevention (CDC), Society for Assisted Reproductive Technology (SART), National Health Service (NHS), Indian Fertility Society (IFS), British Fertility Society (BFS), European Society of Human Reproduction and Embryology (ESHRE), Association for Fertility and Reproductive Health (AFRH), German Society of Reproductive Medicine (DGRM), Canadian Fertility & Andrology Society (CFAS), Indian Society for the Study of Reproduction and Fertility (ISSRF), Spanish Fertility Society (Sociedad Española de Fertilidad-SEF), Japan Society for Reproductive Medicine, National Registry of Assisted Reproductive Technology and Surrogacy Registry, Journal of Human Reproductive Sciences, American Congress of Obstetricians and Gynecologists (ACOG), European Society of Human Genetics (ESHG); ACS Journals; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.

      Secondary data was collected and analyzed to determine the overall size of the global preimplantation genetic testing market, which was then validated through primary research. These sources also provided key information about major players, market classification, and segmentation based on industry trends, regional and country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

      Preimplantation Genetic Testing Market

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the preimplantation genetic testing market. These methods were also used extensively to estimate the size of various market segments.

      Preimplantation Genetic Testing Market

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.

      Market Definition

      Preimplantation genetic testing (PGT) examines embryos during in vitro fertilization (IVF) before possible transfer to a woman's uterus. This is done to test a range of genetic problems that can cause implantation failure, miscarriage, and birth defects in a resulting child.

      Preimplantation genetic testing refers to the three types of tests that may be performed on embryos during IVF:

      • Preimplantation genetic screening for abnormal chromosome number (PGT-A)
      • Preimplantation genetic testing for monogenic (individual) disease (PGT-M)
      • Preimplantation genetic testing structural rearrangement (PGT-SR) for known chromosomal misarrangements such as inversion and translocation.

      The study offers an in-depth analysis of the preimplantation genetic testing market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key preimplantation genetic testing product and service providers.

      Stakeholders

      • Contract research organizations (CROs)
      • Contract development and manufacturing organizations (CDMOs)
      • In vitro fertilization (IVF) centers and fertility clinics
      • Life science companies
      • Fertility clinics
      • Academic & research institutes
      • Private research institutes
      • Venture capitalists & investors
      • Market research & consulting firms
      • Government associations
      • Medical institutions & universities
      • Hospitals & clinics

      Report Objectives

      • To define, describe, and forecast the preimplantation genetic testing market based on procedure type, technology, product & service, application, type of cycle, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall preimplantation genetic testing market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the preimplantation genetic testing market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the preimplantation genetic testing market
      • To benchmark players within the preimplantation genetic testing market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

      Get the Full Preimplantation Genetic Testing Market Report

      Full forecast, segment splits, and company analysis for all Preimplantation Genetic Testing Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status